HC Wainwright & Co. Maintains Buy on Unicycive Therapeutics, Lowers Price Target to $2.5
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Ed Arce maintains a Buy rating on Unicycive Therapeutics (NASDAQ:UNCY) but lowers the price target from $4.5 to $2.5.
August 15, 2024 | 5:24 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
HC Wainwright & Co. analyst Ed Arce maintains a Buy rating on Unicycive Therapeutics but lowers the price target from $4.5 to $2.5.
The maintained Buy rating suggests continued confidence in the company's prospects, but the lowered price target indicates tempered expectations for short-term performance. This mixed signal is likely to result in a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100